Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices

• Published in: Biology of blood and marrow transplantation Vol. 26; no. 7; pp. e147 - e160
• Main Authors: Ardura, Monica, Hartley, David, Dandoy, Christopher, Lehmann, Leslie, Jaglowski, Samantha, Auletta, Jeffery J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2020; American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc
• Subjects: Adenosine Monophosphate - analogs & derivatives; Adenosine Monophosphate - therapeutic use; Alanine - analogs & derivatives; Alanine - therapeutic use; Betacoronavirus - immunology; Betacoronavirus - pathogenicity; Bone Marrow Transplantation; Cell therapy; Clinical Laboratory Techniques - methods; Coronavirus; Coronavirus Infections - diagnosis; Coronavirus Infections - epidemiology; Coronavirus Infections - immunology; Coronavirus Infections - therapy; COVID-19; COVID-19 Testing; Drug Combinations; Education, Distance - organization & administration; Hematopoietic cell transplantation; Hematopoietic Stem Cell Transplantation; Humans; Hydroxychloroquine - therapeutic use; Immunization, Passive - methods; Immunocompromise; Infection Control; Information Dissemination - methods; Lopinavir - therapeutic use; Pandemics; Pneumonia, Viral - diagnosis; Pneumonia, Viral - epidemiology; Pneumonia, Viral - immunology; Pneumonia, Viral - therapy; Practice Guidelines as Topic; Real-Time Polymerase Chain Reaction; Ritonavir - therapeutic use; SARS-CoV-2; Severe acute respiratory syndrome; Severity of Illness Index; Tissue Donors - education; Tissue Donors - supply & distribution; COVID-19; SARS-CoV-2; Hematopoietic cell transplantation; Coronavirus; Cell therapy; Severe acute respiratory syndrome; Bone marrow transplantation; Immunocompromise
• ISSN: 1083-8791; 1523-6536
• DOI: 10.1016/j.bbmt.2020.04.018

The full impact of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on the field of hematopoietic cell transplantation (HCT) is unknown. This perspective paper reviews the following: current COVID-19 epidemiology, diagnosis, and potential therapies; care considerations unique to HCT recipients; and the concept of a learning network to assimilate emerging guidelines and best practices and to optimize patient outcomes through facilitating shared learning and experience across transplantation centers.